文献速递免疫规划卫生政策与健康促进

15价或20价肺炎球菌结合疫苗用于美国65岁及以上成人及19岁及以上有基础疾病成人的成本效果

Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions.
PubMed 文献 · Vaccine · 2024-12-06

研究基于概率队列模型,评估美国65岁及以上成人(基于年龄)和19-64岁有基础疾病成人(基于风险)接种PCV20单独或PCV15序贯PPSV23相比旧建议的成本效果。基于年龄接种两种方案均节省成本;基于风险加年龄接种PCV20节省成本,而PCV15序贯PPSV23每获得一个QALY增加成本412,111美元(95%CI:270,295,694,869)。

要点

  • 65岁基于年龄接种PCV20单独或PCV15序贯PPSV23均节省成本。
  • 基于风险加年龄接种PCV20单独节省成本。
  • 基于风险加年龄接种PCV15序贯PPSV23每QALY增加成本412,111美元(95%CI:270,295,694,869)。

核心结论

  • 在美国成人中,用PCV20单独或PCV15序贯PPSV23替代既往建议改善了健康结局;除基于风险加年龄使用PCV15序贯PPSV23导致每QALY成本增加外,其他干预均降低成本。

研究设计与样本

  • 采用概率队列模型,模拟所有65岁人群(基于年龄)和19岁人群(基于风险至64岁,65岁起基于年龄)。
  • 使用基于电子表格的蒙特卡洛模拟软件估计不同疫苗策略下的免疫成本、医疗成本、非医疗成本和总体疾病负担。
  • 模型追踪住院侵袭性肺炎球菌疾病(IPD)及住院和门诊非菌血症性肺炎(NBP)。

主要发现

  • 65岁基于年龄使用PCV20单独或PCV15序贯PPSV23均显示节省成本(改善健康结局并节省成本)。
  • 基于风险(19-64岁)加基于年龄(65岁)使用PCV20单独节省成本。
  • 基于风险加年龄使用PCV15序贯PPSV23增加质量调整生命年(QALY),但每获得一个QALY增加成本412,111美元(95%CI:270,295,694,869)。

关键数值与推荐

  • 2021年6月,免疫实践咨询委员会(ACIP)推荐对所有未接种过肺炎球菌结合疫苗的65岁及以上成人(基于年龄)以及19-64岁有增加肺炎球菌疾病风险的基础疾病成人(基于风险),使用PCV20单独或PCV15序贯PPSV23。
  • 该推荐替代了此前对这些人群使用PPSV23联合或不联合13价肺炎球菌结合疫苗(PCV13)的建议。
  • 成本以2021年美元报告,所有未来成本和结局按每年3%贴现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In June 2021, the Advisory Committee on Immunization Practices (ACIP) recommended use of either 20-valent pneumococcal conjugate vaccine (PCV20) alone or 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all PCV-unvaccinated adults aged ≥65 years (age-based) and for adults aged 19-64 years with conditions that increase the risk for pneumococcal disease (risk-based). This recommendation replaced a previous recommendation for PPSV23 with or without 13-valent pneumococcal conjugate vaccine (PCV13) for these groups. OBJECTIVE: We conducted a cost-effectiveness analysis of age-based and risk-based use of either PCV15 in series with PPSV23 or PCV20 alone when compared to previous recommendations. METHODS: We utilized probabilistic cohort models of all 65-year-olds (age-based) and 19-year-olds (risk-based through age 64 years and age-based at age 65 years). A spreadsheet-based Monte Carlo simulation software was used to estimate immunization costs, medical costs, non-medical costs, and overall disease burden under different vaccine strategies. The model tracked inpatient invasive pneumococcal disease (IPD) and non-bacteremic pneumonia (NBP) in inpatient and outpatient settings. One-way sensitivity analyses incorporated indirect effects of prospective pediatric vaccination with PCV15 and PCV20 on adult IPD and NBP incidence. Costs were reported in 2021 US dollars. All future costs and outcomes were discounted at 3 % per year. RESULTS: Age-based use of either PCV20 alone or PCV15 in series with PPSV23 at age 65 years were both shown to be cost-saving (improved health outcomes and saved costs). Combined cost-effectiveness of risk-based (19-64 years) plus age-based (65 years) (risk-and-age-based) use of PCV20 alone was cost-saving, whereas use of PCV15 in series with PPSV23 increased quality-adjusted life years (QALYs) but cost $412,111 (95 % CI: 270,295, 694,869) per QALY gained. CONCLUSION: In U.S. adults, replacing the previous recommendations with PCV20 alone or PCV15 in series with PPSV23 improved health outcomes. Except for risk-and-age-based use of PCV15 in series with PPSV23 that resulted in increased cost per QALY gained, the interventions also reduced costs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rosenthal M, Stoecker C, Leidner AJ, et al. Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions. Vaccine. 2024. PMID: 39645434. doi:10.1016/j.vaccine.2024.126567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。